Tempest Therapeutics, Inc. TPST
0.83
(0.02)
(2.35%)
as of 25 Sep
- Market cap
- $14.4M
- P/E
- 0.0×
Follow TPST
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | — | — | 83.76 |
P/FCF ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | — | — | (3.65) |
P/B ratio |
— | — | — | — | — | — | — | — | — | 0.51 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | — | 0.51 |
EV/Sales |
— | — | — | — | — | — | — | — | — | (91.41) |
EV/EBITDA |
— | — | — | — | — | — | — | — | — | 0.76 |
EV/Operating CF |
— | — | — | — | — | — | — | — | — | 0.97 |
EV/FCF |
— | — | — | — | — | — | — | — | — | 0.93 |
Quick Ratio |
2.33 | 2.13 | 4.17 | 4.29 | 2.59 | 5.92 | 5.17 | 8.15 | 4.56 | 8.66 |
Current Ratio |
2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 | 8.82 |
Net Debt/EBITDA |
0.29 | 0.73 | 1.15 | 0.57 | 1.33 | 0.86 | 1.42 | 2.87 | 0.20 | 1.46 |
Debt/Assets |
0.00% | 0.00% | 12.14% | 25.57% | 22.54% | 11.01% | 0.50% | 0.68% | 3.90% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.23 | 0.65 | 0.46 | 0.14 | 0.01 | 0.01 | 0.18 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Operating CF/Net income |
1.02 | 0.79 | 0.93 | 0.87 | 0.92 | 0.99 | 0.92 | 0.87 | 0.24 | 0.75 |
Capex/Depreciation |
0.00 | (1.12) | (0.45) | (0.88) | (0.36) | (0.15) | (0.38) | (1.12) | (0.14) | (0.89) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (203.63%) | (182.35%) | (131.42%) | (131.70%) | 173.23% | 430.58% | (67.02%) | 98.16% | 833.08% | (69.99%) | |
| (89.91%) | (89.90%) | (60.38%) | (59.85%) | (58.90%) | (39.27%) | (56.04%) | (52.35%) | (118.83%) | (63.00%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (2,110.92%) | (748.22%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(472.34%) | (230.67%) | (92.76%) | (133.58%) | (56.55%) | (108.44%) | (71.95%) | (36.94%) | (540.54%) | (75.60%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,314.09% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7,537.98% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,434.76% |
Graham Net Nets |
— | — | — | — | — | — | — | — | — | 1.87 |
Graham Number |
— | — | — | — | — | — | — | — | — | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | — | — | (152.83%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | — | (117.59%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.36 |
Operating CF per Share |
(6.46) | (15.39) | (23.08) | (34.99) | (89.05) | (528.25) | (586.37) | (2,993.29) | (15,646.15) | (5,612.18) |
Capex per Share |
0.00 | (0.20) | (0.14) | (0.63) | (0.46) | (1.39) | (5.65) | (4.56) | (3.08) | (235.09) |
Free Cash Flow per Share |
(6.46) | (15.59) | (23.22) | (35.62) | (89.51) | (529.64) | (592.02) | (2,997.85) | (15,649.23) | (5,847.27) |
Cash per Share |
1.86 | 14.10 | 33.09 | 35.17 | 177.80 | 522.78 | 903.44 | 9,837.47 | 13,556.15 | 10,398.91 |
Shareholders Equity per Share |
1.61 | 8.91 | 22.58 | 20.39 | 123.90 | 497.61 | 851.65 | 9,255.95 | 3,383.85 | 9,838.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.61 | 8.91 | 22.58 | 20.39 | 123.90 | 497.61 | 851.65 | 9,255.95 | 3,383.85 | 9,838.00 |
Free Cash Flow |
(26.82) | (33.46) | (27.53) | (31.63) | (26.09) | (19.07) | (41.62) | (23.68) | (20.34) | (64.32) |
Working Capital |
4.96 | 17.25 | 30.95 | 25.67 | 48.94 | 16.60 | 58.61 | 73.61 | 15.65 | 103.24 |
Capital Expenditures |
— | (0.43) | (0.17) | (0.56) | (0.13) | (0.05) | (0.40) | (0.04) | 0.00 | (2.59) |
Net Current Asset Value |
(1.99) | 9.11 | 15.53 | 4.97 | 31.84 | 14.88 | 56.03 | 72.47 | 4.33 | 102.12 |
EV/EBIT |
— | — | — | — | — | — | — | — | — | 0.74 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.96 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (12,597.24%) |
Price to Operating Income |
— | — | — | — | — | — | — | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.44 | 0.44 | 0.45 | 0.60 | 0.34 | 0.31 | 0.32 | 0.00 | 0.00 | 0.52 |
Cash ROIC |
(190.78%) | (68.66%) | (39.02%) | (52.57%) | (25.91%) | (51.28%) | (36.00%) | (15.62%) | (89.23%) | (30.24%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.73 | 1.23 | 0.64 | 0.60 | 0.02 | 0.00 | 1.95 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 222.94 | 284.82 | 479.65 | 518.70 | 22,789.69 | 0.00 | 147.53 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Receivables |
— | — | — | — | — | 0.77 | 1.80 | 1.68 | 1.68 | — |
Average Payables |
1.74 | 1.65 | 0.98 | 1.05 | 1.03 | 1.28 | 1.75 | 1.65 | 1.74 | 2.77 |
Average Assets |
29.21 | 46.55 | 48.85 | 59.66 | 48.05 | 48.92 | 79.52 | 51.94 | 71.18 | 130.58 |
Average Common Equity |
12.90 | 22.95 | 22.44 | 27.11 | (16.34) | (4.46) | 66.50 | (27.70) | (10.15) | 117.53 |
Columns are period end dates